beta 2-Microglobulin in clinical medicine.
beta 2-Microglobulin in clinical medicine.
复制标题
临床医学中的β2-微球蛋白。
DOI：
--
复制
发表时间：
1980
期刊：
影响因子：
--
通讯作者：
P. Evrin
中科院分区：
文献类型：
--
作者：
F. Karlsson;L. Wibell;P. Evrin
正常人体内β 2微球蛋白的产生相当稳定，约为0.13毫克/小时。分解代谢几乎完全通过肾脏消除。蛋白质很容易通过肾小球膜；随后，超过99.9%过滤后的β 2微球蛋白在近端小管中被重吸收和降解，最终尿液中只有约5微克/小时的蛋白质出现。近端肾小管功能障碍导致尿浓度增高。血清β 2微球蛋白水平由肾小球滤过率和合成率决定。在恶性肿瘤中，有时会观察到随着血清水平升高而产生的增加，主要是在晚期，在淋巴样b细胞的肿瘤增殖或与淋巴系统激活相关的炎症性疾病中。在体液中，除血浆和尿液外，β 2-微球蛋白的含量似乎经常反映局部产生。在这篇综述中，介绍了β 2微球蛋白在临床医学中的现状和用途。
The production of beta 2-microglobulin in normal subjects is quite constant, about 0.13 mg/h . kg. The catabolism almost exclusively through renal elimination. The protein readily passes the glomerular membrane; subsequently more than 99.9% of the filtered beta 2-microglobulin is reabsorbed and degraded in the proximal tubules, only about 5 micrograms/h of the protein appearing in the final urine. Proximal tubular dysfunction leads to an increased urinary concentration. The serum level of beta 2-microglobulin is determined by the glomerular filtration rate and the rate of synthesis. Increased production, with raised serum levels, is sometimes observed in malignancy--mainly at an advanced state, in conditions with neoplastic proliferation of lymphoid B-cells or in inflammatory disorders connected with an activation of the lymphopoetic system. In body fluids, other than plasma and urine, the content of beta 2-microglobulin seems to often reflect a local production. In this review a presentation of the current status and usefulness of beta 2-microglobulin measurements in clinical medicine is included.